Thrivent Financial for Lutherans Sells 3,128 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Thrivent Financial for Lutherans trimmed its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 4.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,871 shares of the company’s stock after selling 3,128 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.08% of Pediatrix Medical Group worth $520,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the second quarter valued at about $31,000. Innealta Capital LLC bought a new stake in Pediatrix Medical Group in the 2nd quarter worth about $33,000. Nisa Investment Advisors LLC boosted its position in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in Pediatrix Medical Group in the second quarter worth about $72,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Pediatrix Medical Group in the second quarter valued at $81,000. 97.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

MD has been the subject of a number of recent analyst reports. UBS Group lifted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Truist Financial boosted their price target on Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a report on Monday. Finally, Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their price target for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.90.

Insider Transactions at Pediatrix Medical Group

In other news, CFO C Marc Richards sold 32,562 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the transaction, the chief financial officer now owns 192,785 shares of the company’s stock, valued at approximately $1,943,272.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO C Marc Richards sold 32,562 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the transaction, the chief financial officer now directly owns 192,785 shares in the company, valued at approximately $1,943,272.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is currently owned by insiders.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $11.83 on Wednesday. The business has a 50-day simple moving average of $10.59 and a two-hundred day simple moving average of $9.00. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $13.01. The firm has a market cap of $995.46 million, a price-to-earnings ratio of -13.92, a price-to-earnings-growth ratio of 1.87 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.31 by $0.03. The firm had revenue of $504.30 million during the quarter, compared to analyst estimates of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. Pediatrix Medical Group’s revenue was up .7% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 EPS. On average, analysts expect that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.